Invention Grant
- Patent Title: Heterocyclic compound and use thereof
-
Application No.: US16811426Application Date: 2020-03-06
-
Publication No.: US11440883B2Publication Date: 2022-09-13
- Inventor: Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike , Kohei Takeuchi , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tohru Miyazaki , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: JP2017-150685 20170803,JP2017-248495 20171225
- Main IPC: C07D211/56
- IPC: C07D211/56 ; C07D211/36 ; C07D405/06 ; A61P25/26 ; C07D409/10 ; A61P25/00 ; C07D205/04 ; C07D207/14 ; C07D401/06 ; C07D401/10 ; C07D401/14 ; C07D403/06 ; C07D405/10 ; C07D405/12 ; C07D413/06 ; C07D417/06 ; C07D417/14
Abstract:
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Public/Granted literature
- US20200207715A1 HETEROCYCLIC COMPOUND AND USE THEREOF Public/Granted day:2020-07-02
Information query
